Safety and efficacy of sphenopalatine ganglion blockade in children: initial experience

Dance, Logan; Aria, David; Schaefer, Christof; Kaye, Robin; Yonker, Marcy; Towbin, R

doi:10.1016/j.jvir.2016.12.595

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These procedures were performed under fluoroscopy using 4% lidocaine spray. 10 There has not been any documented report using SPGB to treat PDPH in the pediatric population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sphenopalatine Ganglion Block for Postdural Puncture Headaches in a Thrombocytopenic Adolescent Young Adult: A Case Report

Lo¹,

Shi²,

Kim³

2021

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The epidural blood patch is the gold-standard therapy to treat postdural puncture headaches from dural puncture when conservative therapies fail. However, an epidural blood patch is contraindicated in patients with coagulopathy and thrombocytopenia (platelet count of 60,000/µL) due to concerns of an epidural hematoma. We present a case of an adolescent with acute lymphocytic leukemia, thrombocytopenia, and persistent postdural puncture headaches. The patient was successfully treated with a sphenopalatine ganglion nerve block at the bedside without any side effects and complications.

show abstract

“…These procedures were performed under fluoroscopy using 4% lidocaine spray. 10 There has not been any documented report using SPGB to treat PDPH in the pediatric population.…”

Section: Discussionmentioning

confidence: 99%

“…Dance and colleagues had demonstrated the safety and efficacy of SPGB in migraine treatment between the ages 7 to 18 years of age. These procedures were performed under fluoroscopy using 4% lidocaine spray 10. There has not been any documented report using SPGB to treat PDPH in the pediatric population.…”

Section: Discussionmentioning

confidence: 99%

Sphenopalatine Ganglion Block for Postdural Puncture Headaches in a Thrombocytopenic Adolescent Young Adult: A Case Report

Lo¹,

Shi²,

Kim³

2021

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…In a published abstract from the 2017 annual scientific meeting for the Society of International Radiology, the outcomes of 310 SPB blocks in 200 pediatric patients aged 7-18 with refractory chronic migraine is reported. 42,43 Patients again rated their pain on a 1-10 scale both before and after treatment. Headache severity decreased by an average of 2 points at 10-minutes posttreatment.…”

Section: Sphenopalatine Ganglion Block In Childrenmentioning

confidence: 99%

Review of Interventional Therapies for Refractory Pediatric Migraine

Peck

Zeien

Patel

et al. 2023

Health Psychology Research

View full text Add to dashboard Cite

This is a review of the latest and seminal evidence in pediatric migraine. It covers the etiology and pathophysiology known today, and then will review treatment options, efficacy and safety, quality of data and indications. Though migraine is usually regarded as an infliction in adults, it is not uncommon in the pediatric population and affects up to 8% of children. Children may experience migraine differently than adults, and present not only with headache but also frequent gastrointestinal symptoms. They are frequently shorter in duration than in adults. Traditional migraine treatment in adults is less effective in children. In this population, adjunct therapies – such as interventional techniques – should be considered when traditional treatment fails, including Botulinum Toxin A (BTA) injections, peripheral nerve and ganglion blocks. BTA injections are FDA approved for migraine prophylaxis in adults, but currently not in children; however, recent evidence shows efficacy and safety in pediatric migraine management. Nerve blocks stop nociceptive afferent fibers through injection of local anesthetics, and it may be associated with the local injection of corticosteroids. Although more common in adults, recent data suggests they are safe and effective in children and adolescents. Blocking the sphenopalatine ganglion can be achieved through nasal approach, and achieves a similar action by blocking the entire ganglion. Interventional techniques may provide a key component in the alleviation of this otherwise debilitating chronic migraine pain. Though most studies have been performed in adults, new studies provide encouraging results for treatment in children.

show abstract

“…In general, few reports have been published on peripheral nerve blocks with local anesthetics or devices in children [49]. In 2017, an abstract reported 133 SPG procedures performed in 85 patients aged 7-18 years as acute treatment for migraine, which decreased headache pain 10 min after the procedure with no complications [69]. Recently, a prospective case series evaluated the SPG block for the prevention of chronic daily headache in 17 adolescents, receiving multiple blocks using a medical device: a benefit on the Patient's Global Impression of Change (PGIC) score after three months of treatment with no adverse events was reported [68].…”

Section: Acute Treatmentsmentioning

confidence: 99%

Emerging Pharmacological Treatments for Migraine in the Pediatric Population

Iannone

Cesaris

Geppetti

2022

Life

View full text Add to dashboard Cite

Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. Few clinical trials have been performed specifically on primary headache in pediatric populations using acute and preventative treatments, often with conflicting findings. The limited high-quality data on the effectiveness of treatments are also due to the high placebo effect, in terms of reductions in both the frequency and intensity of migraine attacks in the pediatric population. The recent introduction of calcitonin gene-related peptide (CGRP) pathway inhibitors and ditans is changing the treatment of migraine, but the majority of the data are still limited to adulthood. Thus, few drugs have indications for migraine treatment in the pediatric age group, and limited evidence gives guidance as to the choice of pharmacotherapy. Herein, we review the current evidence of pharmacological treatments and ongoing clinical trials on acute and preventative treatments in the pediatric population with migraine.

show abstract

Safety and efficacy of sphenopalatine ganglion blockade in children: initial experience

Cited by 6 publications

References 0 publications

Sphenopalatine Ganglion Block for Postdural Puncture Headaches in a Thrombocytopenic Adolescent Young Adult: A Case Report

Sphenopalatine Ganglion Block for Postdural Puncture Headaches in a Thrombocytopenic Adolescent Young Adult: A Case Report

Review of Interventional Therapies for Refractory Pediatric Migraine

Emerging Pharmacological Treatments for Migraine in the Pediatric Population

Contact Info

Product

Resources

About